Skip to main content

Table 1 Characteristics of P reserved R atio I mpaired S piro m etry (PRISm), smoking control, and COPD subjects in COPDGene using fixed threshold criteria

From: Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene

  Control subjects PRISm COPD
n 4388 1257 3690
Age 56.7 (8.4)* 57.2 (8.2) 63.4 (8.5)*
Sex (% Male) 52.9* 46.1 55.6*
African American 41.2 43.1 22.7*
Current smoker 59.7* 63.8 40.7*
Pack-years 37.2 (20.2)* 42.7 (24.2) 53.0 (27.5)*
Body Mass Index 28.9 (5.8)* 31.8 (7.3) 28.1 (6.3)*
FEV1% predicted 97.5 (11.5)* 70.2 (8.4) 50.2 (18.0)*
FVC% predicted 96.6 (11.9)* 71.5 (9.1) 76.3 (17.3)*
FEV1/FVC 0.79 (0.05)* 0.77 (0.05) 0.50 (0.13)*
Bronchodilator Responsiveness 10.0* 13.7 36.6*
Total Lung CapacityCT% predicted 92.3 (14.6)* 79.9 (13.5) 101.5 (17.1)*
Segmental wall area percentage 60.1 (2.9)* 62.5 (3.1) 62.9 (3.1)*
Percent emphysema (% LAA-950insp) 2.0 (2.5)* 1.4 (2.5) 13.0 (12.8)*
Percent gas trapping (% LAA-856exp) 11.0 (9.7) 10.4 (9.1) 39.2 (20.8)*
Pi10 3.65 (0.11)* 3.73 (0.14) 3.72 (0.14)*
6 minute walk distance (feet) 1491.5 (350.7)* 1266.6 (366.9) 1174.8 (397.0)*
MMRC Dyspnea score 0.8 (1.2)* 1.5 (1.5) 2.1 (1.4)*
Resting O2 saturation 97.1 (2.0)* 96.5 (2.5) 94.7 (3.6)*
Chronic bronchitis 12.6* 17.8 28.2*
Short acting beta-agonist use 12.0* 28.1 65.7*
Long acting beta-agonist use 4.4* 13.3 49.1*
Inhaled corticosteroid use 5.5* 16.4 51.2*
Oral corticosteroid use 0.5* 2 5.9*
Congestive heart failure 1.3* 4.6 5.4
Coronary artery disease 7.5* 13.5 16.5*
Diabetes mellitus 11.6* 21.6 13.1*
Hypertension 36.3* 49.1 50.6
Hyperlipidemia 34.3* 42.5 41.4
History of blood clot 2.8* 5.2 5.7
Peripheral vascular disease 1.3* 2.7 3.4
History of stroke 1.6* 3.5 3.6
Gastrointestinal reflux disease 20.3* 25.9 30.3*
History of compression fracture 3.4* 5.4 6.2
Currently employed 37.3* 28.9 25.3*
Physician-diagnosed asthma 11.4* 21.1 24.6*
  1. Data are presented as mean (standard deviation) or percent. Preserved Ratio Impaired Spirometry (PRISm) defined as: FEV1/FVC ≥ 0.7 & FEV1 < 80% predicted. Control subjects defined as: FEV1/FVC ≥ 0.7 & FEV1 ≥ 80% predicted. Chronic Obstructive Pulmonary Disease (COPD) subjects defined as: FEV1/FVC < 0.7 & FEV1 < 80% predicted.
  2. *Denotes univariate p-value < 0.05 when compared to PRISm subjects.
  3. Bronchodilator responsiveness considered present if the change in FEV1 or FVC was >200 mL and ≥ 12% predicted following administration of short acting inhaled beta-agonist.
  4. MMRC = modified Medical Research Council.